What are the appropriate indications, dosing regimen, contraindications, and monitoring recommendations for modafinil?

Modafinil: Clinical Use Guide

Primary Indications

Modafinil is strongly recommended as first-line therapy for narcolepsy and idiopathic hypersomnia in adults 1. The 2021 American Academy of Sleep Medicine (AASM) guidelines provide the highest level of evidence, designating modafinil with a STRONG recommendation for both conditions—meaning clinicians should use it under most circumstances.

FDA-Approved Indications 2:

• Narcolepsy (excessive daytime sleepiness)
• Obstructive sleep apnea (OSA) - for residual sleepiness despite adequate CPAP therapy
• Shift work sleep disorder (SWD)

Additional Conditional Recommendations 1:

• Hypersomnia secondary to Parkinson's disease
• Hypersomnia secondary to traumatic brain injury
• Hypersomnia secondary to myotonic dystrophy
• Pediatric narcolepsy (conditional, with important caveats below)

Important limitation: Modafinil treats excessive sleepiness but does NOT treat cataplexy or the underlying airway obstruction in OSA 2.

---

Dosing Regimen

Standard Adult Dosing 2:

For Narcolepsy or OSA:

• 200 mg once daily in the morning (standard dose)
• Maximum: 400 mg/day if needed
• Evidence supports that 400 mg can be given as a split dose (morning + midday) for patients with breakthrough late-afternoon/evening sleepiness 3, 4

For Shift Work Sleep Disorder:

• 200 mg once daily, taken approximately 1 hour before the start of the work shift 2

Special Populations:

Severe hepatic impairment:

• Reduce dose to half the recommended dose (100 mg daily) 2

Geriatric patients:

• Consider lower doses due to altered pharmacokinetics 2

Pediatric patients:

• Use is conditional and carries significant warnings (see contraindications)
• When used: typically 200-400 mg/day 1

---

Contraindications and Critical Warnings

Absolute Contraindications 2:

• Known hypersensitivity to modafinil or armodafinil

FDA Black Box Warning for Pediatrics 1:

• NOT FDA-approved for patients < 17 years due to case reports of:
  • Stevens-Johnson syndrome (SJS)
  • Psychosis
• Despite this, AASM gives a conditional recommendation for pediatric narcolepsy when benefits outweigh risks

Serious Warnings Requiring Immediate Discontinuation 2:

1. Serious rash/Stevens-Johnson Syndrome: Discontinue at first sign of rash unless clearly not drug-related
2. Angioedema and anaphylaxis: Discontinue immediately if suspected
3. Multi-organ hypersensitivity reactions: Discontinue if suspected

Pregnancy and Reproductive Considerations 1, 2:

Pregnancy Category: May cause fetal harm

• Animal data shows fetal toxicity
• 2018 pregnancy registry data showed higher rates of major congenital anomalies in children exposed in utero
• Avoid in pregnancy unless absolutely necessary

Contraceptive interaction:

• Modafinil reduces effectiveness of oral contraceptives via enzyme induction 2
• Use alternative or additional contraceptive methods during treatment and for 1 month after discontinuation

Cardiovascular Precautions 2:

• Use caution in patients with known cardiovascular disease
• Monitor blood pressure—clinically significant increases are rare but possible
• Not recommended in moderate-to-severe hypertension

Psychiatric Precautions 2:

• Use caution in patients with history of:
  • Psychosis
  • Depression
  • Mania
• Consider discontinuation if new psychiatric symptoms develop

---

Monitoring Recommendations

Initial Assessment:

• Baseline blood pressure and heart rate
• Screen for cardiovascular disease history
• Screen for psychiatric history (psychosis, depression, mania)
• Pregnancy test in women of childbearing potential
• Liver function tests if hepatic impairment suspected

Ongoing Monitoring 2, 5:

Clinical monitoring:

• Assess degree of sleepiness frequently—persistent sleepiness despite treatment requires re-evaluation
• Advise patients to avoid driving or dangerous activities if still excessively sleepy
• Monitor for emergence of rash (discontinue immediately if occurs)
• Monitor for psychiatric symptoms (mood changes, psychosis, suicidal ideation)

Cardiovascular monitoring:

• Periodic blood pressure and heart rate checks, especially in patients with cardiovascular risk factors
• Clinical trials showed minimal cardiovascular effects, but individual monitoring is prudent 5

Laboratory monitoring:

• No routine laboratory monitoring required in healthy patients
• Clinically significant laboratory abnormalities occurred in <1% of patients in trials 5

What NOT to Monitor:

• Sleep architecture: Modafinil does not affect polysomnography parameters 5
• Routine ECGs: Not necessary unless clinically indicated

---

Common Adverse Effects 1, 2, 5:

Most common (≥5%):

• Headache (most common: 34-52%)
• Nausea (11%)
• Nervousness
• Insomnia
• Diarrhea
• Rhinitis
• Back pain
• Anxiety
• Dizziness
• Dyspepsia
• Dry mouth

Key point: Adverse events are generally mild-to-moderate and similar across all approved indications. Dose-related adverse effects are uncommon.

---

Drug Interactions 2:

Significant interactions requiring action:

1. Steroidal contraceptives (ethinyl estradiol): Reduced efficacy—use backup contraception
2. Cyclosporine: Blood levels may be reduced—monitor levels
3. CYP2C19 substrates (omeprazole, phenytoin, diazepam): Increased exposure—may need dose adjustment

---

Controlled Substance Status 2:

• Schedule IV federally controlled substance
• Has potential for abuse or dependency, but significantly lower than traditional stimulants 6, 7
• No significant withdrawal phenomena reported upon discontinuation 6

---

Clinical Pearls and Pitfalls:

When to use split dosing:

• If patients report satisfactory morning/midday control but breakthrough sleepiness in late afternoon/evening, switch from 200 mg once daily to 400 mg split dose (e.g., 200 mg morning + 200 mg midday) 3, 4

What modafinil does NOT treat:

• Cataplexy (use sodium oxybate, venlafaxine, or clomipramine instead) 1, 8
• Underlying sleep apnea obstruction (optimize CPAP first) 2

Advantages over traditional stimulants:

• Lower abuse potential 6, 7
• No rebound hypersomnia after discontinuation 6
• Does not affect nocturnal sleep architecture 5
• Better tolerated long-term 6

Red flags requiring immediate discontinuation:

• Any rash
• Signs of angioedema (facial swelling, difficulty breathing)
• New psychiatric symptoms (psychosis, severe mood changes)